• Enzalutamide regimen prolongs metastasis-free survival in nonmetastatic prostate cancer

    8 days ago - By Healio

    A combination of enzalutamide and leuprolide significantly extended metastases-free survival for men with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, according to a company press release.
    Results of the randomized phase 3 EMBARK trial also showed a statistically significant and clinically meaningful improvement of metastasis-free survival among men who received enzalutamide monotherapy vs. placebo and leuprolide, the companies announced.
    The double-blind, three-arm trial enrolled 1,068 men randomly assigned to 160 mg
    Read more ...

     

  • Drug combination may reduce the risk of prostate cancer progression, death

    Drug combination may reduce the risk of prostate cancer progression, death

    9 days ago - By News Medical

    TALAPRO-2, a study led by Neeraj Agarwal, MD, FASCO, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%.
    Read more ...